Switching Adult Patients with Warm Autoimmune Hemolytic Anemia from Rituximab to IMAAVY

SUMMARY

• The company cannot recommend any practices, procedures, or usage of IMAAVY that deviate from the approved labeling.
• Please refer to the local labeling for information on the appropriate use of IMAAVY in patients with warm autoimmune hemolytic anemia (wAIHA).
• In the ENERGY study, patients who received rituximab treatment within 3 months prior to screening were excluded.¹
  • Prior rituximab use was reported in 42.1% (16/38), 55.3% (21/38), and 48.7% (19/39) of patients in the IMAAVY 30 mg/kg every 4 weeks (Q4W), 15 mg/kg every 2 weeks (Q2W), and placebo (PBO) groups, respectively.

CLINICAL DATA

Phase 2/3 Study: ENERGY

Fattizzo et al (2026)¹ evaluated the efficacy and safety of IMAAVY in adults with wAIHA in a phase 2/3 multicenter, randomized, double-blind, PBO-controlled study.

Exclusion Criteria

• Patients who received rituximab treatment within 3 months prior to screening were excluded.¹

Results

• Prior rituximab use was reported in 42.1% (16/38), 55.3% (21/38), and 48.7% (19/39) of patients in the IMAAVY 30 mg/kg Q4W, 15 mg/kg Q2W, and PBO groups, respectively.

Literature Search

A literature search of MEDLINE^®, EMBASE^®, BIOSIS Previews^®, and DERWENT^® (and/or other resources, including internal/external databases) was conducted on 31 August 2026.